<DOC>
	<DOCNO>NCT01886651</DOCNO>
	<brief_summary>The purpose study explore impact thiopurine methyltransferase ( TPMT ) activity risk HDM-related bone marrow- hepatotoxicity treatment interruption maintenance therapy child ALL . Hypothesis study : Patients TPMT activity compatible TPMT low activity polymorphism increase risk toxicity follow high-dose methotrexate ( HDM ) compare child normal TPMT activity .</brief_summary>
	<brief_title>The Influence Thiopurine Methyltransferase Activity Toxicity After High-dose Methotrexate Childhood Acute Lymphoblastic Leukemia</brief_title>
	<detailed_description>High-dose methotrexate ( HDM ) give concurrently oral 6-mercaptopurine ( 6MP ) may follow myelotoxicity , may necessitate treatment interruption thus interfere efficacy treatment childhood ALL . Several study indicate MTX 6MP act synergistically . It previously report risk significant bone-marrow suppression increase oral 6MP coadministered HDM maintenance therapy reduction dose concurrently give oral 6MP reduce risk significant myelotoxicity follow HDM . MTX may increase bioavailability 6MP inhibition xanthine oxidase , catabolize 6MP . In addition , MTX may inhibition de novo purine synthesis enhance availability 6-thioguanine nucleotide ( 6TGN ) primarily exert cytotoxic effect 6MP . The enzyme TPMT compete formation 6TGN , methylates 6MP thus create relatively non-toxic metabolite . TPMT heterozygous patient one wild type one low-activity allele high risk myelosuppression treatment interruption compare patient TPMT wild type . Furthermore , TPMT heterozygous patient reduce risk relapse high risk secondary malignancy compare patient TPMT wild type . Little publish influence TPMT activity 6MP dosage myelo- hepatotoxicity follow HDM .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<criteria>include NOPHO ALL92 protocol available TPMT phenotype treat least HDMTX 5.0 g/m2 ( + 10 % ) maintenance therapy least one available measurement blood count alanine aminotransferase level 28 day HDMTX HR ALL child Down Syndrome Events maintenance therapy TPMT deficiency</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>15 Years</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>acute lymphoblastic leukemia</keyword>
	<keyword>child</keyword>
	<keyword>6-mercaptopurine</keyword>
	<keyword>methotrexate</keyword>
</DOC>